UBX - Unity Biotech jumps 93% after data for lead asset in diabetic macular edema
- The shares of Unity Biotechnology ( NASDAQ: UBX ) jumped ~93% in the pre-market Friday after the clinical-stage biotech said that its lead product candidate UBX1325 demonstrated a statistically significant treatment effect in patients with diabetic macular edema (DME) in a Phase 2 trial.
- According to 12- and 18-week data from the 65-patient BEHOLD study, a single injection of UBX1325 a, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) compared to a sham control.
- In addition, based on the central subfield thickness (CST), UBX1325 was found to stabilize the retinal structure while those who received the sham treatment experienced a worsening effect.
- Patients enrolled were under regular anti-VEGF therapy such as EYLEA from Regeneron ( REGN ), the current standard of care for DME.
- “Bolstered by positive proof-of-concept data, we believe UBX1325 could represent a much-needed alternative to all other currently available treatments for DME, including the standard of care anti-VEGF therapy,” chief medical officer of Unity ( UBX ) Jamie Dananberg remarked. The company awaits the 24- week data from the study.
For further details see:
Unity Biotech jumps 93% after data for lead asset in diabetic macular edema